Examining the relationship between vascular biomarkers and both microangiopathy and cutaneous fibrosis in systemic sclerosis

Abstract

Objective:

The objective of the study is to explore the pathogenic relationship between vasculopathy and fibrosis in systemic sclerosis through expression of vascular biomarkers.

Methods:

Plasma biomarkers including panVEGF-A, VEGF-A₁₆₅b and angiopoietins (Ang) and clinical parameters were investigated in 53 systemic sclerosis patients and 15 controls. Biopsies of affected skin from 10 systemic sclerosis patients and 5 controls were used to assess expression of hypoxia-inducible factor (HIF1α, -2α) and VEGF-A isoforms. Vasculopathy was assessed using nailfold capillaroscopy (qualitative pattern and intercapillary distance), reperfusion gradient after ischaemic challenge and ultrasound vascularity index (dorsovolar vascularity index). Skin fibrosis was assessed using skin scores and ultrasound (skin thickness, echogenicity and elastography).

Results:

Plasma Ang-2 was increased (p = 0.012) and Ang-1/-2 ratio reduced (p = 0.018) in systemic sclerosis patients compared to controls. Ang-2 progressively increased across nailfold capillaroscopy patterns (p = 0.031) and weakly correlated with intercapillary distance (+0.284, p = 0.05) and reperfusion gradient (−0.356, p = 0.018). Plasma angiopoietins correlated with echogenicity (Ang-1 +0.381, p = 0.006; Ang-2 +0.330, p = 0.022) and elastography (Ang-2 +0.353, p = 0.014). Plasma VEGF-A₁₆₅b correlated with dorsovolar vascularity index (−0.289, p = 0.039). HIF1α and 2α were increased in skin (p = 0.008) with HIF2α predominance. Epidermal HIF2α correlated more strongly with VEGF-A₁₆₅b (+0.709, p = 0.022) than panVEGF-A (+0.552, p = 0.098). Epidermal HIF2α and fibroblast VEGF-A₁₆₅b tended to associate with early and diffuse cutaneous systemic sclerosis. Cutaneous expression of HIF1α (+0.489, p = 0.069) and HIF2α (+0.489, p = 0.064) correlated with intercapillary distance. Epidermal VEGF-A₁₆₅b correlated with skin thickness (−0.672, p = 0.006).

Conclusions:

Increased expression of HIFα and antiangiogenic biomarkers associated with both vasculopathy and fibrosis in systemic sclerosis. Our data highlight the conceivable therapeutic targets of dual inhibitory biomarkers such as Ang-2.

Keywords

Hypoxia-inducible factor vascular endothelial growth factor angiopoietin vasculopathy fibrosis systemic sclerosis

Get full access to this article

View all access options for this article.

References

Vasile

Avouac

Sciarra

, et al. From VEDOSS to established systemic sclerosis diagnosis according to ACR/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey. Clin Exp Rheumatol 2018; 36suppl 113(4): 82–87.

Broz

Aschwanden

Partovi

, et al. Assessment of cutaneous microcirculation in unaffected skin regions by transcutaneous oxygen saturation monitoring and laser Doppler flowmetry in systemic sclerosis. Clin Hemorheol Microcirc 2015; 60(3): 263–271.

Distler

Scheid

, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95: 109–116.

Flower

Barratt

Ward

, et al. The role of vascular endothelial growth factor in systemic sclerosis. Curr Rheumatol Rev 2019; 15(2): 99–109.

Wipff

Dieude

Avouac

, et al. Association of hypoxia-inducible factor 1A (HIF1A) gene polymorphisms with systemic sclerosis in a French European Caucasian population. Scand J Rheumatol 2009; 38(4): 291–294.

Takagi

Kawamoto

Higuchi

, et al. Single nucleotide polymorphisms of the HIF1A gene are associated with susceptibility to pulmonary arterial hypertension in systemic sclerosis and contribute to SSc-PAH disease severity. Int J Rheum Dis 2020; 23(5): 674–680.

Heger

Kerber

Hortmann

, et al. Expression of the oxygen-sensitive transcription factor subunit HIF-1alpha in patients suffering from secondary Raynaud syndrome. Acta Pharmacol Sin 2019; 40: 500–506.

Maciejewska

Sikora

Stec

, et al. Hypoxia-inducible factor-1α (HIF-1α) as a biomarker for changes in microcirculation in individuals with systemic sclerosis. Dermatol Ther 2023; 13(7): 1549–1560.

Zhou

Liu

, et al. 2-Methoxyestradiol inhibits hypoxia-induced scleroderma fibroblast collagen synthesis by phosphatidylinositol 3-kinase/Akt/mTOR signalling. Rheumatology 2018; 57: 1675–1684.

10.

Distler

Jüngel

Pileckyte

, et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 2007; 56(12): 4203–4215.

11.

Ioannou

Pyrpasopoulou

Simos

, et al. Upregulation of VEGF expression is associated with accumulation of HIF-1alpha in the skin of naive scleroderma patients. Mod Rheumatol 2013; 23: 1245–1248.

12.

Ottria

Zimmermann

Paardekooper

, et al. Hypoxia and TLR9 activation drive CXCL4 production in systemic sclerosis plasmacytoid dendritic cells via mtROS and HIF-2α. Rheumatology 2022; 61: 2682–2693.

13.

Kelly

Hackett

Hirota

, et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003; 93: 1074–1081.

14.

Leung

Cachianes

Kuang

, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–1309.

15.

Olsen

BR.

The roles of vascular endothelial growth factor in bone repair and regeneration. Bone 2016; 91: 30–38.

16.

Barratt

Blythe

Jarrett

, et al. Differential expression of VEGF-Axxx isoforms is critical for development of pulmonary fibrosis. Am J Respir Crit Care Med 2017; 196: 479–493.

17.

Byrne

Bouchier-Hayes

Harmey

JH.

Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005; 9(4): 777–794.

18.

Moritz

Schniering

Distler

JHW

, et al. Tie2 as a novel key factor of microangiopathy in systemic sclerosis. Arthritis Res Ther 2017; 19: 105.

19.

Cossu

Andracco

Santaniello

, et al. Serum levels of vascular dysfunction markers reflect disease severity and stage in systemic sclerosis patients. Rheumatology 2016; 55(6): 1112–1116.

20.

Dunne

Keen

Van Eeden

SF.

Circulating angiopoietin and Tie-2 levels in systemic sclerosis. Rheumatol Int 2013; 33(2): 475–484.

21.

Riccieri

Stefanantoni

Vasile

, et al. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 2011; 29(2suppl 65): S46–S52.

22.

Michalska-Jakubus

Kowal-Bielecka

Chodorowska

, et al. Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology 2011; 50(4): 746–755.

23.

Choi

Min

Cho

, et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003; 30(7): 1529–1533.

24.

Manetti

Guiducci

Romano

, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 2011; 109: e14–26.

25.

Manetti

Guiducci

Romano

, et al. Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. Ann Rheum Dis 2013; 72(8): 1425–1427.

26.

Didriksen

Molberg

Fretheim

, et al. Lymphangiogenic factors are associated with pulmonary arterial hypertension in systemic sclerosis. Arthritis Rheumatol 2021; 73: 1277–1287.

27.

Zhan

Liu

, et al. Association of circulating vascular endothelial growth factor levels with autoimmune diseases: a systematic review and meta-analysis. Front Immunol 2021; 12: 674343.

28.

El Gharbawy

Sheha

Bawady

, et al. Vascular endothelial growth factor profile and vitamin D level in systemic sclerosis Egyptian patients. Egypt J Immunol 2021; 28(3): 168–175.

29.

Maurer

Distler

Suliman

, et al. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis 2014; 73(10): 1880–1887.

30.

van den Hoogen

Khanna

Fransen

, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737–2747.

31.

Cutolo

Herrick

Distler

, et al. Nailfold videocapillaroscopic features and other clinical risk factors for digital ulcers in systemic sclerosis: a multicenter, prospective cohort study. Arthritis Rheumatol 2016; 68(10): 2527–2539.

32.

Keberle

Tony

Jahns

, et al. Assessment of microvascular changes in Raynaud’s phenomenon and connective tissue disease using colour Doppler ultrasound. Rheumatology 2000; 39(11): 1206–1213.

33.

Della Rossa

D’Ascanio

Barsotti

, et al. Post-occlusive reactive hyperaemia (POHR) in systemic sclerosis: very early disease (VEDOSS) represents a separate entity compared to established disease. Scand J Rheumatol 2016; 45(5): 408–411.

34.

Flower

Barratt

Hart

, et al. High frequency ultrasound assessment of systemic sclerosis skin involvement: intra-observer repeatability and relationship with clinician assessment and dermal collagen content. J Rheumatol 2020; 48: 867–876.

35.

Khanna

Furst

Clements

, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2017; 2(1): 11–18.

36.

Tang

Babicheva

McDermott

, et al. Endothelial HIF-2alpha contributes to severe pulmonary hypertension due to endothelial-to-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol 2018; 314: L256–L275.

37.

Mittag

Beckheinrich

Haustein

UF.

Systemic sclerosis-related Raynaud’s phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 2001; 81(4): 294–297.

38.

Sulli

Ruaro

Smith

, et al. Progression of nailfold microvascular damage and antinuclear antibody pattern in systemic sclerosis. J Rheumatol 2013; 40(5): 634–639.

39.

Gerlicz

Dziankowska-Bartkowiak

Dziankowska-Zaborszczyk

, et al. Disturbed balance between serum levels of receptor tyrosine kinases Tie-1, Tie-2 and angiopoietins in systemic sclerosis. Dermatology 2014; 228(3): 233–239.

40.

Michalska-Jakubus

Cutolo

Smith

, et al. Imbalanced serum levels of Ang1, Ang2 and VEGF in systemic sclerosis: integrated effects on microvascular reactivity. Microvasc Res 2019; 125: 103881.

41.

Carvalheiro

Lopes

van der Kroef

, et al. Angiopoietin-2 promotes inflammatory activation in monocytes of systemic sclerosis patients. Int J Mol Sci 2020; 21: 9544.

42.

Takahashi

Asano

Akamata

, et al. Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis. Mod Rheumatol 2013; 23(5): 884–890.

43.

Zhou

Tabib

Huang

, et al. Molecular changes implicate angiogenesis and arterial remodeling in systemic sclerosis-associated and idiopathic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2024; 44(8): e210–e225.

44.

Farouk

Hamza

El Bakry

, et al. Dysregulation of angiogenic homeostasis in systemic sclerosis. Int J Rheum Dis 2013; 16(4): 448–454.

45.

Mok

Yiu

Wong

, et al. Low circulating level of CD133+KDR+cells in patients with systemic sclerosis. Clin Exp Rheumatol 2010; 28(5suppl 62): S19–25.

46.

Distler

Del Rosso

Giacomelli

, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4(6): R11.

47.

Avouac

Vallucci

Smith

, et al. Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. Arthritis Res Ther 2013; 15: R55.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.28 MB